Company intelligence / Profile preview
AntoXa Corporation
Toronto, Ontario, Canadaantoxacorp.com ↗
- Ownership
- Private
- Development stage
- Preclinical
01
Overview
AntoXa is developing plant-made monoclonal antibodies and enzyme therapeutics as medical countermeasures for biological and chemical threats. Its lead program is a monoclonal antibody against ricin poisoning in preclinical development. The company also has recombinant ACE2 therapies targeting COVID‑19 in discovery stage. No clinical results have been reported yet.
- Therapeutic areas
- OtherInfectious Diseases
- Modalities
- Monoclonal antibodies (mAbs)EnzymesRecombinant proteins (plant-based)
- Industry
- Biotech
02
Drug pipeline
3 assets2 more assets in the full pipeline.
03
Partnerships
SwiftPharma (collaboration on plant-made mAb against ricin)Defence Research & Development Canada / Canadian Department of National Defence (licensing and research collaboration)
Beyond the preview
Go deeper on AntoXa Corporation.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on AntoXa Corporation.